Allergic Bronchopulmonary Aspergilloses Clinical Trial
Official title:
A Study Evaluating Vitamin D in Allergic Bronchopulmonary Aspergillosis Complicating Asthma
Allergic bronchopulmonary aspergillosis (ABPA) is a immunological pulmonary disorder caused by hypersensitive reaction to spores of Aspergillus fumigatus. The prevalence of disease is about 1-2% in asthmatics and 2-15% in patients with cystic fibrosis. The interest in ABPA stems from the fact that the disease is glucocorticoid-sensitive and early treatment can prevent progression to end-stage lung disease. Recently anti-Th2 therapies have been suggested as treatment for ABPA. Vitamin D has been shown to suppress the Th2 responses and decrease the levels of Th2 interleukins. Hence, the investigators propose to assess the role of vitamin D in treating ABPA.
Allergic bronchopulmonary aspergillosis (ABPA) is a immunological pulmonary disorder caused
by hypersensitive reaction to spores of Aspergillus fumigatus. The prevalence of disease is
about 1-2% in asthmatics and 2-15% in patients with cystic fibrosis. The interest in ABPA
stems from the fact that the disease is glucocorticoid-sensitive and early treatment can
prevent progression to end-stage lung disease.
Systemic steroids remain the mainstay of treatment in ABPA. Antifungal agents are also useful
as they reduce fungal load. Newer therapies like omalizumab (anti immunoglobulin E [IgE]
antibody), inhalational amphotericin and Anti Th2 therapies are being studied.
In pathogenesis of ABPA, there is heightened Th2 activity as a result of type 1
hypersensitive reaction to Aspergillus fumigatus and levels of Th2 cytokines like IL-3, IL-5
and IL-13 and IgE levels are increased in patients with ABPA compared with asthma patients
without ABPA.
Recently anti Th2 therapies have been suggested as treatment for ABPA. Vitamin D has been
shown to suppress the Th2 immunity and decrease the levels of Th2 interleukins. Hence, the
investigators propose to assess the role of vitamin D in treatment of ABPA.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03265366 -
Diagnostic Value of MRI for Allergic Broncho-Pulmonary Aspergilloses
|
N/A |